| abstract |
The present invention relates to a compound of the formula (1) which is a Janus kinase (JAK) inhibitor, a family of genus tyrosine kinases of the Janus kinase, which relates to an inflammatory condition, an autoimmune disease ), proliferative disease, allergy, transplant rejection, disease involving impairment of cartilage turnover, congenital cartilage malformation, and/or interference with IL6 Excessive secretion of related diseases. In particular, the compounds of the invention inhibit JAK1 and/or JAK2 and/or JAK3 subfamilies. The invention also provides a process for the manufacture of a compound of the invention, a pharmaceutical composition comprising a compound of the invention, a tautomeric form thereof, and a pharmaceutically acceptable salt thereof.n□ |